ArticleMedical science monitor : international medical journal of experimental and clinical research2019
Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Alzheimer's Disease: A Comparison of Eyes of Patients with Alzheimer's Disease, Primary Open-Angle Glaucoma, and Preperimetric Glaucoma and Healthy Controls.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- Dietary Melatonin Therapy Alleviates the Lamina Cribrosa Damages in Patients with Mild Cognitive Impairments: A Double-Blinded, Randomized Controlled Study.Medical science monitor : international medical journal of experimental and clinical research · 2020Trial
- Early Detection of Dementia Through Spectralis Optical Coherence Tomography in a Taiwanese Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Evaluation of the Choroidal Thickness and Retinal Nerve Fiber Layer Thickness in Patients with Vasovagal Syncope.Journal of personalized medicine · 2025Article
- A Novel Retinal Nerve Fiber Layer Biomarker of Amyotrophic Lateral Sclerosis (ALS) Identified Using Longitudinal in vivo Ocular Imaging.Eye and brain · 2025Article
- Alzheimer's disease pathophysiology in the Retina.Progress in retinal and eye research · 2024Review
- Retinal thickness and vascular parameters using optical coherence tomography in Alzheimer's disease: a meta-analysis.Neural regeneration research · 2023Article
- Review
- Identification of Alzheimer's Disease by Imaging: A Comprehensive Review.International journal of environmental research and public health · 2023Review
- Huntington's disease and neurovascular structure of retina.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Differentiating Degenerative from Vascular Dementia with the Help of Optical Coherence Tomography Angiography Biomarkers.Healthcare (Basel, Switzerland) · 2022Review
- Protein and Imaging Biomarkers in the Eye for Early Detection of Alzheimer's Disease.Journal of Alzheimer's disease reports · 2021Review
- Ophthalmic Biomarkers for Alzheimer's Disease: A Review.Frontiers in aging neuroscience · 2021Review
- Optical Coherence Tomography in Patients with Alzheimer's Disease: What Can It Tell Us?Eye and brain · 2021Review
- Article
- Alzheimer's and Consciousness: How Much Subjectivity Is Objective?Neuroscience insights · 2021Article
- Ganglion Cell Layer Thinning in Alzheimer's Disease.Medicina (Kaunas, Lithuania) · 2020Review
- Article
- Decreased Retinal Vascular Density in Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI): An Optical Coherence Tomography Angiography (OCTA) Study.Frontiers in aging neuroscience · 2020Article
- Afferent and Efferent Visual Markers of Alzheimer's Disease: A Review and Update in Early Stage Disease.Frontiers in aging neuroscience · 2020Article
- Reflections on the Utility of the Retina as a Biomarker for Alzheimer's Disease: A Literature Review.Neurology and therapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND The aim of this study was to assess and compare peripapillary retinal nerve fiber layer (RNFL) thickness in patients with Alzheimer's disease (AD), primary open-angle glaucoma (POAG), preperimetric glaucoma (PPG), and healthy controls with the use of Spectral Domain Optical Coherence Tomography (SD-OCT). MATERIAL AND METHODS Thirty patients with AD, 30 patients with POAG, 30 patients with PPG, and 30 healthy controls were enrolled in this cross-sectional study. Only 1 randomly selected eye of each patient was analyzed. Every subject underwent a thorough ophthalmological examination and OCT of the optic disc. The peripapillary RNFL thickness in each of the 6 sectors and globally was analyzed. RESULTS The RNFL was thinnest in patients with POAG. The mean RNFL thickness value was 60.97±12.97 µm and it was significantly lower than in healthy controls (106.30±8.95 µm), patients with PPG (93.20±12.04 µm), and AD patients (95.73±13.52 µm). Mean RNFL thickness in patients with AD was significantly lower when compared to healthy controls, and was higher compared to eyes with POAG, while there were no significant differences compared to patients with PPG. CONCLUSIONS Neuronal damage in the central nervous system (CNS) also affects to retinal axons. A major problem is to distinguish the cause for a moderate decrease in the RNFL thickness. This is particularly true for patients with glaucoma who have not been diagnosed with changes in the visual field. It is not possible to distinguish the cause of a mild decrease in the RNFL thickness based on the SD-OCT. This may result in misdiagnosis of glaucoma, unnecessary use of anti-glaucoma eye drops, and a delayed diagnosis of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.